Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
PharmAthene
About
PharmAthene develops medical countermeasures to prevent and treat morbidity and mortality associated with biological and chemical weapons.
- 51 - 100
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $50M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2001
- Number Of Employee
- 51 - 100
- Operating Status
- Active
PharmAthene, Inc., a biodefense company, develops medical countermeasures to prevent and treat morbidity and mortality associated with the use of biological and chemical weapons in the United States. Its products, which are under development, include Valortim, a prophylactic and therapeutic anti-anthrax monoclonal antibody; and Protexia, a recombinant form of human butyrylcholinesterase for clinical use in the treatment of organophosphate intoxication due to exposure to chemical nerve agents. The company was founded in 2001 and is headquartered in Annapolis, Maryland.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 1, 2006 | Post-IPO Equity | — | 1 | — | — | Detail |
| Oct 12, 2004 | Series B | $50M | 1 |
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series B |
Canadian Medical Discoveries Fund
|
— | Post-IPO Equity |
